Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $2.95 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 07/17/2019 04:55:09 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $N/A | $2.95 | $N/A | $N/A | 0 | 07-17-2019 |
$ | $3.06 | $2.95 | $3.11 | $2.61 | 28,297 | 07-16-2019 |
$ | $3.2804 | $3.20 | $3.2804 | $3.20 | 4,627 | 07-15-2019 |
$ | $3.2856 | $3.20 | $3.30 | $3.20 | 3,582 | 07-12-2019 |
$ | $3.28 | $3.1753 | $3.28 | $3.17 | 3,462 | 07-11-2019 |
$ | $N/A | $3.26 | $N/A | $N/A | 99 | 07-10-2019 |
$ | $3.26 | $3.26 | $3.30 | $3.16 | 1,367 | 07-09-2019 |
$ | $3.1501 | $3.28 | $3.29 | $3.15 | 25,300 | 07-08-2019 |
$ | $3.38 | $3.12 | $3.3844 | $3.045 | 14,825 | 07-05-2019 |
$ | $3.36 | $3.20 | $3.43 | $3.20 | 11,102 | 07-03-2019 |
$ | $3.40 | $3.22 | $3.49 | $3.10 | 30,509 | 07-02-2019 |
$ | $3.43 | $3.25 | $3.43 | $3.25 | 1,059 | 07-01-2019 |
$ | $3.55 | $3.35 | $3.60 | $2.93 | 67,671 | 06-28-2019 |
$ | $3.50 | $3.63 | $3.6325 | $3.4101 | 6,113 | 06-27-2019 |
$ | $3.64 | $3.45 | $4.0193 | $3.41 | 125,379 | 06-26-2019 |
$ | $3.58 | $3.65 | $3.75 | $3.4301 | 135,520 | 06-25-2019 |
$ | $3.31 | $3.60 | $3.85 | $3.31 | 30,249 | 06-24-2019 |
$ | $3.4948 | $3.45 | $3.5566 | $3.2501 | 23,344 | 06-21-2019 |
$ | $3.40 | $3.50 | $3.5834 | $3.40 | 23,423 | 06-20-2019 |
$ | $3.37 | $3.40 | $3.5495 | $3.2361 | 30,678 | 06-19-2019 |
News, Short Squeeze, Breakout and More Instantly...
Xynomic Pharmaceuticals Holdings Inc. Company Name:
XYN Stock Symbol:
NYSE Market:
RALEIGH, N.C. and SHANGHAI, June 12, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, Nasdaq: XYN), a clinical stage US-China oncology drug development company, announced that it recently held a pre-IND meeting with the U.S. Food and Drug Admin...
RALEIGH, N.C. and SHANGHAI, June 06, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, Nasdaq: XYN), a clinical stage US-China oncology drug development company, announced that Xynomic has dosed the first patient in a Phase 1/2 trial that combin...
RALEIGH, N.C. and SHANGHAI, May 21, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”), a clinical stage US-China oncology drug development company (Nasdaq: XYN), announced today that long-term follow up data of exceptional responders to abexinos...